Ripretinib
Other Protein Kinase Inhibitors
Sold as Qinlock
- Drug class
- Other Protein Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 3
Overview
Ripretinib is an active pharmaceutical ingredient in the Other Protein Kinase Inhibitors group (L01EX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | April 17, 2026 |
| EU European Union | EMA | 1 | February 11, 2026 |
| CA Canada | Health Canada | 1 | January 9, 2026 |
GBUnited Kingdom· MHRA
1 product
Uses
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
How to take
EUEuropean Union· EMA
1 product
Uses
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
How to take
CACanada· Health Canada
1 product
How to take
5 Missed Dose 2024-08 Table of Contents Certain sections or subsections that are not applicable at the time of preparation of the most recent authorized product monograph are not listed. Recent Major Label Changes .....................................................................................................
2 Part 1: Health Professional Information ................................................................................... 4 1 Indications .......................................................................................................................
1 Pediatrics ............................................................................................................... 2 Geriatrics ...............................................................................................................
4 2 Contraindications ............................................................................................................ 4 3 Serious Warnings and Precautions Box .......................................................................
Drug interactions
Known interactions involving Ripretinib. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB552950004 · revised April 17, 2026
- [2]European Medicines Agency · EMEA/H/C/005614 · revised February 11, 2026
- [3]Health Canada (DPD) · 02500833 · revised January 9, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.